Adial Strikes Exclusive EU AD04 Deal with Molteni, Unlocking $60M Royalties
Adial Pharmaceuticals entered an exclusive framework agreement with Molteni Farmaceutici to commercialize its Phase 3-ready AD04 across Europe, granting Molteni evaluation exclusivity and setting strategic, clinical, manufacturing and commercial terms. The deal’s definitive agreement could yield nearly $60 million in upfront, milestone and tiered royalties for Adial.
1. Collaboration Framework Agreement
Adial Pharmaceuticals signed a collaboration framework agreement granting Molteni Farmaceutici exclusive rights to evaluate, plan and commercialize AD04 across European markets. The framework outlines strategic, clinical, regulatory, manufacturing and commercialization parameters, subject to execution of a final definitive agreement.
2. Financial and Commercial Terms
Under the planned definitive agreement, Adial would receive an upfront payment, development and commercial milestone payments, plus tiered royalties ranging from high single digits to low double digits on net European sales. The aggregate potential value of these payments and royalties is estimated at nearly $60 million.
3. Development Strategy and Intellectual Property
AD04’s Phase 3 program is precision-driven, enrolling patients with a responsive genotype to enhance efficacy and cost efficiency. Adial has filed a new patent covering its genotype-driven analysis, which, if granted, would extend exclusivity to 2045, supporting long-term commercial protection.
4. Future Milestones and Next Steps
Molteni will conduct due diligence and feasibility assessments before finalizing the definitive agreement. Adial plans to initiate its pivotal Phase 3 program soon and is also engaging potential U.S. partners to secure parallel commercialization pathways in North America.